webinar register page

Webinar banner
The epigenetic regulation of breast cancer: Meet the expert, Dr. Steve Chan
Topic: Using unbiased ChIP-Rx analyses to discover a novel role for CTR9 in the epigenetic regulation of PRC2 subtype switching in breast cancer.

Proteintech is delighted to host Dr. Steve Chan from The University of Wisconsin-Madison, as he takes us though their recent paper “The transcriptional elongation factor CTR9 demarcates PRC2-mediated H3K27me3 domains by altering PRC2 subtype equilibrium”, published in the journal Nucleic Acid Research.

Chan and colleagues, under the supervision of Professor Wei Xu, performed quantitative measurement of histone modifications as well as unbiased ChIP-Rx analyses, to show that CTR9 controls the levels and genomic distribution of H3K27me3 (a histone modifier) in breast cancer cells. CTR9 depletion profoundly affects PRC2 subtype switching and generates vulnerability that renders breast cancer cells hypersensitive to PRC2 inhibitors. Their study uncovers a mechanism to provide the basis for therapeutically targeting CTR9-low breast tumors with EZH2 inhibitors.

Following his talk there will be an interactive Q&A session with Dr. Chan.
Certificate of attendance provided.
Registration is free. Can't make the time? The recording will be sent to all registrants.

Proteintech are excited to be collaborating for this event with Active Motif, the industry leader in providing reagents and services for epigenetics research.

May 19, 2022 09:00 AM in Central Time (US and Canada)

Webinar logo
* Required information
Loading

Speakers

Dr Steve Chan
Postdoctoral Research Fellow @University of Wisconsin-Madison, US
Ngai Ting (Steve) Chan received a BS from Fudan University, China, and a PhD in Cancer Biology from McArdle Laboratory for Cancer Research at the University of Wisconsin-Madison. His PhD thesis work in Dr. Wei Xu’s laboratory focused on elucidating the transcriptional network governed by epigenetic mechanisms, and translating this work to develop new cancer therapies. For this, he employed various genomic and bioinformatic approaches to study chromatin structure and epigenetic mechanisms in breast cancer. He is currently continuing his work as a postdoctoral fellow in Dr. Xu’s laboratory, and will look for a postdoctoral position in an eminent chromatin biology laboratory in the near future.